Topic: healthcare

Viatris (VTRS) Sees Revenue Growth and Pipeline Development Boosting Valuation Potential

06/04/2026, 11:31 AM investing growth healthcare

Viatris is experiencing a turnaround with improving sales and margins, driven by a strategic focus on drug development that could enhance its valuation and shareholder value. The company is poised for growth with a promising pipeline and cost-cutting measures that are already yielding positive results.

Confirmed Case of New World Screwworm in Texas Boosts Biotech Stocks Zoetis (ZTS) and Elanco Animal Health (ELAN)

06/04/2026, 10:31 AM investing review healthcare

The discovery of the New World screwworm parasite in Texas livestock has led to increased stock prices for Zoetis and Elanco Animal Health, as investors anticipate heightened demand for treatments. This situation could impact the beef supply chain and market volatility if the parasite spreads further.

Analysts Bank of America upgraded UnitedHealth Group (UNH) to Buy and raised target price to $450 (upside +19%)

06/04/2026, 06:31 AM investing rating_growth Analysts: analysts, Bank of America healthcare

Bank of America has upgraded UnitedHealth Group to a buy rating, citing the company's successful strategic shifts that are expected to enhance earnings and boost share prices significantly.

Analysts BTIG upgraded Medtronic (MDT) to Buy with $90 target price (upside +15%)

06/04/2026, 04:32 AM investing rating_growth Analysts: analysts, BTIG healthcare

BTIG has upgraded Medtronic to a buy rating, citing strong growth potential and a favorable valuation compared to peers, suggesting investors could see significant returns.

Biotech M&A Set for Strongest Year Since Pre-Pandemic as Deal Value Reaches $106 Billion in 2026

06/03/2026, 11:30 PM business review biotech healthcare

The biopharma sector is experiencing a significant surge in mergers and acquisitions, with 2026 poised to become the strongest year since before the pandemic, driven by patent expirations and a favorable market environment.

Eli Lilly’s Business Development Head Jacob Van Naarden Signals Increased M&A Activity as Company Pursues New Opportunities

06/03/2026, 04:33 AM business announcement healthcare

Eli Lilly is leveraging its significant financial strength, driven by its successful weight loss drugs, to pursue an aggressive acquisition strategy aimed at diversifying its drug pipeline and expanding into new therapeutic areas. This shift marks a notable change in Lilly's approach to dealmaking as it seeks to capitalize on its recent growth.

Novo Nordisk Launches Wegovy Weight Loss Pill in the UAE, Its First Market Outside the U.S.

06/03/2026, 01:31 AM announcement healthcare

Novo Nordisk's launch of its weight loss pill Wegovy in the UAE marks a significant expansion into international markets, which could help the company regain market share in the competitive weight-loss drug sector.

Analysts Goldman Sachs initiated coverage of Mobia Medical (MOBI) with a buy rating and a target price of $31, indicating 130% upside

06/02/2026, 05:35 AM investing rating_growth Analysts: analysts, Goldman Sachs healthcare

Goldman Sachs has initiated coverage of Mobia Medical with a buy rating and a price target of $31, indicating a potential 130% upside, highlighting the company's innovative approach in the stroke recovery market.

New Experimental Pill Daraxonrasib Shows Promise in Extending Survival for Advanced Pancreatic Cancer Patients

05/31/2026, 06:31 AM research healthcare

A new experimental drug, daraxonrasib, has shown promising results in extending survival for patients with advanced pancreatic cancer, potentially marking a significant advancement in treatment options for this challenging disease.

Akeso and Summit Therapeutics' Lung Cancer Drug Reduces Death Risk by 34% in Late-Stage Trial

05/31/2026, 05:32 AM business research healthcare

The experimental lung cancer drug ivonescimab from Akeso and Summit Therapeutics has shown a 34% reduction in the risk of death in a late-stage trial, which could position it as a significant player in the oncology market, particularly for squamous non-small-cell lung cancer patients.